MSB 0.00% $1.74 mesoblast limited


  1. 6,067 Posts.
    lightbulb Created with Sketch. 1011
    Celgene is lurking in the background.

    1. They purchased 45m shares in MSB for $3.82 in April 2015 for a 6 month first right of refusal to certain disease fields.

    2. They extended the the first right of refusal for a further 6 months on 16 October 2015
    with respect to Mesoblast’s proprietary mesenchymal lineage adult stem cell product candidates for the prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection. This would have expired in April 2016.

    In 2015 Celgene was busy and acquired Receptos for 7.2B

    Celgene differentiates itself when it comes to deal-making. Celgene puts together multiple different deal structures -- collaborative partnerships, follow-on licensing deals, equity only acquisitions, you name it -- based on what the smaller target company needs. By allowing the latter to retain some of its own products, and not capping the financial upside, the little guy keeps pulling for all its worth.

    They may re-enter the scene and snap up a bargain and a do a deal to cherry pick Tier 1 products and/or any emerging new products.

watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Mkt cap ! $1.128B
Open High Low Value Volume
$1.72 $1.75 $1.70 $3.782M 2.192M

Buyers (Bids)

No. Vol. Price($)
2 17102 $1.74

Sellers (Offers)

Price($) Vol. No.
$1.75 12000 1
View Market Depth
Last trade - 16.10pm 14/05/2021 (20 minute delay) ?
0.000 ( 0.93 %)
Open High Low Volume
$1.73 $1.76 $1.70 540314
Last updated 15.59pm 14/05/2021 (live) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.